Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Lenalidomide in Relapsed Lymphoma
NCT02875067Phase 2Terminated
- Sponsor
- NYU Langone Health
- Start
- Aug 2016
- Primary completion
- Oct 2017
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL), sponsored by NYU Langone Health. Started Aug 2016; status: terminated.
02
Drugs
03
Conditions
Hodgkin lymphoma (HL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT02875067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02875067.